Carcinoma, Squamous Cell of Head and Neck Clinical Trial
Official title:
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a prospective, observational, non-interventional, multicenter, post-marketing surveillance study to mainly collect safety information from subjects with locally advanced and recurrent/metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) treated with cetuximab based on the locally approved label.
Cetuximab is an immunoglobulin G1 (IgG1) monoclonal antibody that enhances the effects of
some common chemotherapy agents and radiotherapy and demonstrates minimal overlapping
toxicities with these approaches. This prospective, observational, non-interventional and
multi-centric post marketing surveillance study is being conducted to collect safety
information from subjects with locally advanced or recurrent/metastatic SCCHN treated with
cetuximab based on the locally approved label. Study plans to enroll 200 to 300 subjects,
who are eligible for cetuximab treatment according to the indication in the approved label
of cetuximab by Taiwan Health Authority. Data related to subjects' demographics, relevant
tumor history, and laboratory information (hematology, biochemistry) will be captured and
analyzed descriptively.
OBJECTIVES
Primary objective:
• To obtain safety information on the use of cetuximab in subjects with SCCHN according to
the regulatory approved label and in a regular clinical setting
Secondary objectives:
• To gather clinical efficacy information of the treatment
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Terminated |
NCT02277184 -
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT02585973 -
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
|
Phase 1 | |
| Completed |
NCT01836029 -
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03088059 -
Biomarker-based Study in R/M SCCHN
|
Phase 2 | |
| Recruiting |
NCT06003231 -
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
|
Phase 2 | |
| Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
| Completed |
NCT02242916 -
State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study
|
N/A | |
| Recruiting |
NCT01876693 -
A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
| Terminated |
NCT02655068 -
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03509012 -
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03799744 -
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT03109158 -
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03485209 -
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
|
Phase 2 | |
| Completed |
NCT01307267 -
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
|
Phase 1 | |
| Terminated |
NCT02822482 -
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
|
Phase 1/Phase 2 | |
| Completed |
NCT02101034 -
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
|
Phase 1/Phase 2 |